https://www.selleckchem.com/pr....oducts/spop-i-6lc.ht
Two patients developed a low-titre inhibitor against rpFVIII, neither experienced any complications. Discussion In our real world experience, susoctocog-alfa was proven to be an effective and safe therapeutic option for patients with AHA, also at a lower than recommended dosage. In our report, the appearance of low-titre inhibitors.Background Platelet transfusions are necessary to prevent and treat haemorrhages in thrombocytopenic patients or those with severe platelet dysfunction. In Latin American countries, including Argentina, bl
Like
Comment
Share
